Dept Environmental Health Sciences, Johns Hopkins University, Baltimore, MD 21205, USA.
Eur J Pharm Biopharm. 2011 Apr;77(3):338-49. doi: 10.1016/j.ejpb.2010.12.027. Epub 2010 Dec 30.
Mechanistic toxicology has evolved by relying, to a large extent, on methodologies that substitute or complement traditional animal tests. The biotechnology and informatics revolutions of the last decades have made such technologies broadly available and useful, but regulatory toxicology has been slow to embrace these new approaches. Major validation efforts, however, have delivered the evidence that new approaches do not lower safety standards and can be integrated into regulatory safety assessments. Particularly in the EU, political pressures, such as the REACH legislation and the 7th Amendment to the cosmetic legislation, have prompted the need of new approaches. In the US, the NRC vision report calling for a toxicology for the 21st century (and its most recent adaptation by EPA for their toxicity testing strategy) have initiated a debate about how to create a novel approach based on human cell cultures, lower species, high-throughput testing, and modeling. Lessons learned from the development, validation, and acceptance of alternative methods support the creation of a new approach based on identified toxicity pathways. Conceptual steering and an objective assessment of current practices by evidence-based toxicology (EBT) are required. EBT is modeled on evidence-based medicine, which has demonstrated that rigorous systematic reviews of current practices and meta-analyses of studies provide powerful tools to provide health care professionals and patients with the current best scientific evidence. Similarly, a portal for high-quality reviews of toxicological approaches and tools for the quantitative meta-analyses of data promise to serve as door opener for a new regulatory toxicology.
机制毒理学的发展在很大程度上依赖于替代或补充传统动物测试的方法。过去几十年的生物技术和信息革命使这些技术广泛可用且有用,但监管毒理学一直缓慢接受这些新方法。然而,主要的验证工作提供了证据表明,新方法不会降低安全标准,并且可以整合到监管安全评估中。特别是在欧盟,政治压力,如 REACH 法规和化妆品法规的第 7 修正案,促使需要新的方法。在美国,NRC 呼吁 21 世纪毒理学的愿景报告(以及 EPA 为其毒性测试策略对其进行的最新改编)引发了一场关于如何基于人类细胞培养、低种属、高通量测试和建模来创建新方法的辩论。替代方法的开发、验证和接受所获得的经验教训支持基于已确定毒性途径创建新方法。需要基于循证毒理学 (EBT) 的概念指导和对当前实践的客观评估。EBT 是基于循证医学的,循证医学已经证明,对当前实践的严格系统审查和研究的荟萃分析为医疗保健专业人员和患者提供当前最佳科学证据提供了强大工具。同样,为毒理学方法和数据定量荟萃分析提供高质量评论的门户有望成为新监管毒理学的切入点。